Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424-Reference-Cited by-同舟云学术

Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424

Published:2020-07 Issue:4 Volume:107 Page:720-725
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Fisher Barbara J.,Pugh Stephanie L.,Macdonald David R.,Chakravatri Arnab,Lesser Glenn J.,Fox Sherry,Rogers C. Leland,Werner-Wasik Maria,Doyle Thomas,Bahary Jean-Paul,Fiveash John B.,Bovi Joseph A.,Howard Steven P.,Michael Yu Hsiang-Hsuan,D’Souza David,Laack Nadia N.,Barani Igor J.,Kwok Young,Wahl Daniel R.,Strasser Jon F.,Won Minhee,Mehta Minesh P.

Funder

NRG Oncology Operations

NRG Oncology Statistical and Data Management Center

NRG Biospecimen Bank

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference19 articles.

1. Radiation and procarbazine, CCNU and vincristine in low-grade glioma;Buckner;NEJM,2016

2. Prognostic factors for survival in adult patients with cerebral low-grade glioma;Pignatti;J Clin Oncol,2002

3. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844;Karim;Int J Radiat Oncol Biol Phys,1996